Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

3.340 +0.110 (+3.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine
Via Investor Brand Network
Recap: Vistagen Therapeutics Q3 Earnings
 
Via Benzinga
VistaGen Therapeutics's Earnings: A Preview
 
Via Benzinga
VistaGen Therapeutics Earnings Preview
 
Via Benzinga
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
From Vistagen
Via Business Wire
Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027
Learn the potency of lesser-known stocks and explore their fundamental edge in technology distribution, food retail, and biotechnology. 
Via InvestorPlace
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Announces Participation at Upcoming Stifel 2024 Virtual CNS Days
Via Investor Brand Network
Vistagen to Present at Stifel 2024 Virtual CNS Days
From Vistagen
Via Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at TD Cowen Conference
Via Investor Brand Network
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
From Vistagen
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Revolutionary Biotech Stocks Poised for 10X Surge
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities. 
Via InvestorPlace
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation. 
Via InvestorPlace
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Releases Q3 2024 Financial Report, Corporate Update
Via Investor Brand Network
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
3 Penny Stocks to Buy for the Next Bull Run: February 2024
As the market pivots in 2024, dive into the dynamic world of penny stocks, revealing the top choices for February's exhilarating bull run. 
Via InvestorPlace
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q3 Results, Conference Call
Via Investor Brand Network
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
From Vistagen
Via Business Wire
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
With our strengthening economy, you need to invest in penny stocks that will deliver high future returns, these three are your best bets. 
Via InvestorPlace
Topics Economy
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) AV-101 to Receive Patent from EPO to Treat Neuropathic Pain
Via Investor Brand Network
Topics Intellectual Property
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
From Vistagen
Via Business Wire
Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment
William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety... 
Via Benzinga
Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst
Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder... 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2024 Financial Report, Corporate Update
Via Investor Brand Network
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
From Vistagen
Via Business Wire
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
Vistagen to Present at Stifel 2023 Healthcare Conference
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Plans to Present Positive Study Results at Conferences in November
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback